September 2024. Volume 20. Number 3

More evidence on the efficacy and safety of nirsevimab: enough for universal use?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al.; HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023;389:2425-35.

Reviewers: Ochoa Sangrador C1, Buñuel Álvarez JC2.
1Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
2CS Santa Isabel. Zaragoza. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 20/06/2024
Acceptance date: 03/07/2024
Publication date: 10/07/2024

Abstract

Authors´ conclusions: nirsevimab prevents hospitalization and severe hospitalization due to respiratory syncytial virus in lower respiratory tract infection. 

Reviewers´ commentary: nirsevimab appears effective and safe, at least in the short term. There are doubts about the clinical importance of the magnitude of the effect, so alternatives to the current universal immunization strategy should be considered, such as evaluating exclusive immunization of children under three months of age or the combination of the vaccine in pregnant women with immunization in high-risk infants.

How to cite this article

Ochoa Sangrador C, Buñuel Álvarez JC. Más evidencia sobre la eficacia y seguridad de nirsevimab: ¿suficiente para su uso universal? Evid Pediatr. 2024;20:29.

AVC | Critically appraised articles

Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al.; HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023;389:2425-35.

Reviewers: Ochoa Sangrador C1, Buñuel Álvarez JC2.
1Servicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
2CS Santa Isabel. Zaragoza. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 20/06/2024
Acceptance date: 03/07/2024
Publication date: 10/07/2024

How to cite this article

Ochoa Sangrador C, Buñuel Álvarez JC. Más evidencia sobre la eficacia y seguridad de nirsevimab: ¿suficiente para su uso universal? Evid Pediatr. 2024;20:29.

10/07/2024

Linked Comment